Alpa Laboratories Ltd

Dematerialisation processing and listing

• Securities received for dematerialisation were confirmed to the depositories.
• Securities dematerialised have been listed on the relevant stock exchange.
• Physical certificates for dematerialisation were mutilated and cancelled; depository name substituted as registered owner within 15 days.

Alpa Laboratories Ltd: Trading Window closed from October 1, 2026 till the expiry of 48 hours after the unaudited financial results for the half year ending September 30, 2026 become generally available information; The Trading Window will open 48 hours after the said financial results are declared to the Stock Exchanges

Alpa Laboratories Limited - Trading Window Closure

Appointment details

• Ms. Diksha Jaswani appointed as Company Secretary cum Compliance Officer (KMP) of Alpa Laboratories Ltd.
• Appointment effective from 17 September 2026.
• Reason: appointment as Company Secretary cum Compliance Officer.
• Profile: qualified CS, Associate Member of ICSI, Membership No. A80495, experienced in ROC filings.
• Disclosures: No relationship with directors or promoters.
• Designation: KMP; authorised for governance roles.
• Term: Not Applicable.
• Shareholding: Nil.

Financials

• Standalone revenue 12,153.02 Lacs; Consolidated 12,156.64 Lacs.
• Standalone net profit 1,406.91 Lacs; Consolidated 1,412.59 Lacs.
• YoY declines due to softer demand and pricing pressure.
• Earnings per share: Basic 6.69; Diluted 6.69.
• Dividend not recommended for the year; policy on company website.
• Share capital unchanged at ₹2,104.06 Lacs; debt/equity 0.01x.

Operations & Capex

• Manufacturing facilities WHO-GMP and ISO certified.
• Single operating segment: drugs and chemicals.
• Nigeria expansion planned via Alpa Biopharm with Blueseal; not yet incorporated.
• Subsidiary Norfolk Mercantile Private Limited 100% owned; merger pending.
• Current borrowings ₹150.81 Lacs; debt/equity 0.01.
• Capex details not disclosed; ongoing investment in capability building.

Governance & Board

• Board size ten; five executive and five independent; two women directors.
• Independent Directors held meeting March 9, 2026; performance review.
• KMP changes: Srashti Chopra resigned; Yashoda Patidar served briefly; replacement in progress.
• Independent Director Mrs. Radhika Biyani appointed Aug 2026 for five-year term.

Audit & Compliance

• Statutory Auditor: M/s CH Padliya & Co; no qualifications.
• Secretarial Auditor: M/s Shilpesh Dalal & Co; no qualifications.
• Internal Audit: M/s S.S. Gandhi; reports to Audit Committee.
• CFO/MD certification confirms compliance with Code of Conduct.

CSR & ESG

• CSR Committee: Pravin Shah (Chair), Valecha, Lunawat; four meetings.
• CSR spend 2025-26: ₹80.21 Lakh; avg. net profit ₹19.85 Lakh; set-off ₹60.15 Lakh.
• CSR project: Shree Hiraba Charitable Trust; education and elderly care; 80 Lakh.

Shareholders & AGM

• AGM 38th on 30 Sept 2026 via VC; cut-off 23 Sept 2026; 1000 attendees.
• Dematerialisation: 99.98% of shares demat; NSDL & CDSL.
• Promoters: Paresh Chawla 34.26%; Mahendra Chawla 13.82%; Shitul Shah 10.15%.

Subsidiary & Merger

• Norfolk Mercantile Private Limited subsidiary 100% owned.
• Merger scheme pending before NCLT; potential synergies noted.

Risks & Outlook

• Risks: regulatory compliance, pricing, raw materials, FX, litigation.
• Outlook: export diversification, branded generics, government tenders; growth path.

Director changes and committee reconstitution

• Cessation of Jyoti Jain as Independent Director effective 21 July 2026.
• Appointment of Radhika Biyani as Independent Director (Additional) effective on DIN allotment (Sept 5, 2026).
• DIN 11918173 allotted; appointment subject to member approval at AGM or postal ballot.
• Intervening period between cessation and appointment due to search, due diligence, and DIN allotment.
• Board reconstituted Audit Committee, Nomination & Remuneration Committee, Stakeholders Relationship Committee, and Risk Management Committee.
• Profile: Radhika Biyani, Independent Director, with 2+ years private-sector experience.

Financials (Standalone & Consolidated)

• Standalone revenue from operations: 2,393.05 lacs; total income: 2,975.98 lacs.
• Standalone PAT: 103.84 lacs; basic EPS: 0.52.
• Consolidated revenue from operations: 2,969.35 lacs; Consolidated PAT: 98.04 lacs.

Board actions & AGM

• Board approved unaudited standalone and consolidated results for quarter ended 30 Jun 2026.
• Board approved notice of 38th AGM.

Operations & Compliance

• Company operates in a single segment: Drugs & Chemicals.
• Independent auditors issued unmodified review on both standalone and consolidated results.

Board meeting date

• Correct date is 13 August 2026 at 3:00 PM; 14 August was a typographical error.

Meeting Details & Agenda

• Board scheduled on 13 August 2026 at 03:00 PM at the registered office.
• Consider unaudited standalone and consolidated quarterly results for quarter ended 30 June 2026.
• Approve the notice for the 38th AGM.

Proposed Nigeria venture

• Approval in principle to explore establishing an overseas Nigerian entity named Alpa Biopharm Limited with Blueseal.
• Not yet incorporated; no investment or ownership details disclosed; terms to be determined subject to regulatory approvals.
• Proposed activities include pharmaceutical and healthcare-related business.